Having visited several European Society of Cardiology (ESC) Congresses, this time the plan was to explore famous American College of Cardiology (ACC) annual Congress. For a long time American way of making science dominated over not only Europe but the rest of the world. Is it still holds true? Probably the answer is not simple, nevertheless, the glimpse of true American perspective can be tasted in real only on the American soil. The 65th ACC Congress was taken place between 2nd till 4th April in Chicago, Illinois at the gargantuan McCormick Convocation Centre located just at the bank of magnificent Michigan lake. The first striking difference was the weather! When in Poland and rest of Europe, the spring was in full swing, the north-west part of the USA was griped in the frosty cold with an average temperature of minus five. Not to mention the icy winds for which Chicago is famous and called the windy-city. This is not an exaggeration, please do believe me! But now a little about the Congress itself.

As expected, the Congress venue was visited by thousands of participants, however, it should be noted that ESC annual Congresses host definitely more people. Surly, there are many reasons behind this but perhaps participation in the American congresses is quite expensive for most non-US doctors, not to mention firm travel restrictions. In the beginning attendees were welcomed by a special taped welcome address from the First Lady Michelle Obama, who highlighted Let’s Move campaign (whole nation program to increase fitness) and also thanked ACC for promoting healthy lifestyle. This was one of the main topic of the congress, indeed. ACC experts start questioning traditional American way of life, including junk food, sweets, smoking and call for an effective implantation of nutrition counselling and smoking-cessation. Obsessed with new technology, the ACC experts see great opportunities for arising e-health approach and Big Data. Another big topic, that was extensively discussed, is the ongoing medical education and maintenance of certification (MOC). Americans are very serious about that and this is something we should really learn or even copy from them. In order to practice in the US, it is obligatory for EVERYONE to be a subject for MOC. This is absolutely right and we can only envy the Americans that they were able to enforce such regulations, not in theory (as it is many European countries, including Poland) but in practice.

Surely, to present the rich scientific content of the Congress is not possible. Let me just focus on several key trials that will shape the future of cardiology. Firstly, Professor Sailm Yusuf from Hamilton, Canada presented the HOPE-3 trail that supports the broader use of statin. The investigators used a combination of two moderate-doses of anti-hypertensive drugs plus statin in intermediate-risk population and found significant reduction of events in the long-term observation. The subsequent analyses confirmed that statins were primarily responsible for the effect. The ongoing debate on the optimal use of dual antiplatelet therapy (DAPT) in stable coronary artery disease and acute coronary syndromes also took place during the event. Referring to the most recent DAPT studies, the ACC issued the special the recommendations. The key massage is that following stent implantation, class I recommendation for DAPT is minimum of 6 to 12 months. However, longer DAPT duration beyond 12 months may be considered (class IIb) in patients with high ischemic but low bleeding risk. On the contrary, shorter duration is recommended when the clinical profile is reversed. Another reminder of changing landscape is the result of the PARTNER-2A trail that demonstrated similar rates of death from disabling stroke or any cause in high-risk patients with aortic stenosis treated with trans-catheter aortic valve replacement (TAVR) and surgical aortic valve replacement. The authors stated that TAVR is the treatment of choice in most patients with aortic stenosis who are at high risk for early death and major complications from conventional surgery. Additionally, there were presented several important trials from the heart failure (HF) area. Professor John McMurray from Glasgow, UK presented long-awaited results of the ATMOSPHERE trial that

Figure 1. Doctor Pawel Rubis in front of his poster during the session
tested the hypothesis that direct renin inhibition with Aliskiren will be superior to ACE-I (enalapril) in the treatment of HF. The study layout was complex and included open-label run-in phase when patients were on both enalapril and aliskiren to be later randomized into three study arms of: aliskiren alone, aliskiren and enalapril and enalapril alone. However, despite huge effort the main results of the study were as follows: the addition of aliskiren to an evidence-based dose of enalapril led to more adverse events without an increase in benefit. Professor McMurray concluded that there is probably a ceiling to RAS blockade in HF, above which there is no further benefit.

Doctor Michel Gold presented the results of the joint American-European INOVATE-HF trial on the role of vagal stimulation in HF. The study hypothesis was to increase vagal tone, which is diminished in HF, via electrical pre-ganglionic cervical vagus nerve stimulation. Although positive trends were noted in NYHA class, 6-minute walking distance and quality of life, nevertheless, this therapy did not reduce the incidence of HF events or all-cause mortality among patients with NYHA III functional status and a reduced ejection fraction. The ixCELL-DCM Trial: Transendocardial Injection of ixmyelocel-T in Patients with Ischemic Dilated Cardiomyopathy, was very innovative study that focused on regenerative therapies as an attractive approach in HF. The authors used – ixmyelocel-T, which is an autologous, bone marrow derived, multicellular therapy, consisted of CD90+/mesenchymal stem cells (MSC) and CD45+/CD14+/M2-like macrophages. This cell-product was injected into myocardium of HF patients and there were no safety issues regarding the procedure. The results of the study seems to be promising as ixmyelocel-T resulted in a significant reduction in cardiac events driven by both mortality and cardiac hospitalizations at 12 months compared to placebo. The authors concluded that ixmyelocel-T may be an attractive option for NYHA Class III/IV patients with ischemic HF who have exhausted optimal medical and device therapy.

Finally, just few words about our own scientific activities. Doctor Pawel Rubis, who was the representative from the Krakow Center, presented the results of the study entitled "Extracellular Matrix Turnover is not Related to the Duration of the Disease in Dilated Cardiomyopathy" during the basic science session on cardiomyopathies. The quality of studies, coming from top US and Japan centers, were very high and interesting discussions and exchange of thoughts and ideas were made.
Aims and scope
Journal of Rare Cardiovascular Diseases (JRCD) is an international, quarterly, peer-reviewed journal that keeps cardiologists up-to-date with rare disorders of heart and vessels. Topics covered include congenital heart defects, cardiomyopathies, rhythm abnormalities, rare forms of arterial hypertension, pulmonary hypertension, cardiac tumors and other rare diseases affecting heart and vessels such as connective tissue diseases, metabolic disorders, neuro-muscular diseases and other unclassified rare diseases.

Instructions for authors
The Journal will consider for publication articles written in English.

Types of papers
The following types of papers will be considered for publication in JRCD:
Original articles: word limit 4000 words, 40 references, no more than 6 figures/tables
Review articles: word limit 5000 words, 50 references, no more than 5 figures
Brief Report: word limit 2000 words, 20 references, no more than 4 figures
Case Report: word limit 3500 words, 30 references, no more than 5 figures.
Letters to editor: up to 600 words

Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission
All articles must be submitted using an electronic submission system at: www.jrcd.eu.

Title page
The title page should include:
• Type of paper
• The name(s) of the author(s)
• A concise and informative title
• The affiliation(s) and address(es) of the author(s)
• The e-mail address, telephone and fax numbers of the corresponding author
• Declaration of conflict of interest

Abstract
Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.

Keywords
Please provide 4 to 6 keywords which can be used for indexing purposes.

Text
Text Formatting
Manuscripts should be submitted in Word.
Use a normal, plain font (e.g., 12-point Times Roman) for text.
Use italics for emphasis.
Use the automatic page numbering function to number the pages.
Do not use field functions.
Use tab stops or other commands for indents, not the space bar.
Use the table function, not spreadsheets, to make tables.
Use the equation editor or MathType for equations.
Save your file in doc format. Do not submit docx files.

Headings
Please use no more than three levels of displayed headings.
Original article should consist of the following sections: Background, Methods, Results, Discussion, Conclusions, References.
Case reports should include the following headings: Case presentation, Review of literature, Patient management and follow-up, References.

Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.

Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data).
Footnotes to the title or the authors of the article are not given reference symbols.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full.

Scientific style Please always use internationally accepted signs and symbols for units (SI units).
Generic names of drugs are preferred; if trade names are used, the generic name should be given at first mention.

References
Reference citations in the text should be identified by numbers in square brackets [ ].
The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.
The entries in the list should be numbered consecutively. 
The example:
Please, list the first three authors and add “et al.”

Tables
All tables are to be numbered using Arabic numerals.
Tables should always be cited in text in consecutive numerical order.
For each table, please supply a table caption (title) explaining the components of the table.
Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
Footnotes to tables should be indicated by superscript lower-case letters and included beneath the table body.

Artwork / Figure
For the best quality final product, it is highly recommended that you submit all of your artwork – photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the highest standards with the greatest accuracy to detail. The published work will directly reflect the quality of the artwork provided.
Supply all figures electronically.
Indicate what graphics program was used to create the artwork.

Figure Numbering
All figures are to be numbered using Arabic numerals.
Figures should always be cited in text in consecutive numerical order.
Figure parts should be denoted by lowercase letters (a, b, c, etc.).
Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Permissions
If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Publisher will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Electronic Supplementary Material
We accept electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online. This feature can add dimension to the author’s article.
Supply all supplementary material in standard file formats.
Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.
For each supplementary material, please supply a concise caption describing the content of the file.

Ethical standards
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements.

Conflict of interest
Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research. They should also state that they have full control of all primary data and that they agree to allow the journal to review their data if requested.
Therefore the manuscript must be accompanied by the “Conflict of Interest Disclosure Form”. To download this form, please follow the hyperlink on the right.

Copyright transfer
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.

Disclaimer
The authors, editors and publisher will not accept any legal responsibility for any errors or omissions that may be made in this publication.
The publisher makes no warranty, express or implied, with respect to the material contained herein.